English
NeuroVascular Coupling (NVC) means that increased metabolic activity in neurons calls for increased blood supply. Disruption of NVC in the brain is at the core of several pathologies, including ischemic stroke, Alzheimer ‘s Disease (AD), and hypertension induced cognitive deficits. A precise characterization of NVC will provide biomarkers for the evolution of these diseases, and may ultimately lead to the development of therapies. In humans, however, the only optical window to a neuro-vascular network in our body is the eye as the retinal neurovascular network is an integral part of the brain. As such, NVC is a core mechanism in the retina too, and NVC disruption is involved in the most common retinal diseases - Diabetic Retinopathy (DR), Glaucoma and Age-related Macular Degeneration (AMD). It can be assessed by illuminating photoreceptor neurons with flickering light, and measuring short-term blood flow evolution (over a few seconds) in response to the light stimulation. Many techniques have been used to document NVC in the retina but these methods lack spatial resolution both for stimulation and vascular imaging. A high spatial resolution in NVC observation is required as blood flow control in the retina is finely localized, DR and AMD start with focal lesions, and NVC affects the various layers of retinal microvessels differently. The goal of the EyeWin project is to provide an advanced clinical tool to probe local neurovascular coupling in the retina at the micrometer and millisecond scale. NVC can be monitored by looking at changes in vessel caliber, blood flow and oximetry, in response to stimulation. The system will selectively stimulate pathological areas in the central retina (typically a few 100µm size) with a precision of a few micrometers, which represents an unprecedented resolution in NVC studies. Subsequent vascular response biomarkers will be imaged at the micrometer and millisecond scale. The project will rely on an existing set-up, Clovis3D, developed for high resolution laser photocoagulation and embedding colocalized SD-OCT and AOFIO en-face imaging, thus representing a powerful tool for NVC investigation. Imaging will be performed in the infrared to prevent any stray light stimulation of the retina. Vessel caliber, blood flow or oxygen saturation maps will be generated at each retinal zone. Areas of abnormality in biomarker maps will be highlighted in image processing, to provide the clinician with a visual representation of areas of reduced retinal function, which he can then target for therapy. The efficacy of this therapy can then be monitored using the same method. First, clinical needs will be assessed based on an existing image database and preliminary clinical tests on commercial devices, in order to define the most relevant biomarkers, as well as the optimal observation and stimulation parameters. These requirements will be translated into system specifications. Identified evolutions of the bench, required to adapt and optimize stimulation, will be performed. Novel vascular functional imaging techniques, based on latest developments on the PARIS Pathfinder, will be improved and implemented on EyeWin setup. To perform clinical trials in safe and ergonomic conditions, this setup will be brought up to a clinical grade tool, compliant with ANSM requirements. After validation of the final setup and associated softwares, a clinical campaign will be carried out on numerous patients to shine a new light on the retinal neurovascular network. The project relies on a well-established partnership between clinicians (CIC1423), a research lab specialized in technology transfer (Onera) and an international market leader in industry (Quantel Medical), developed through various prior projects, including Clovis3D. Progress is expected in both diagnosis and therapy of pathologies associated with cerebrovascular dysfunctions with potentially high societal impact.
